ERBB2 and invasive breast carcinoma: The aim of this study was to determine the association of SES (measured using the deprivation category at the area of residence) and wider sociodemographic characteristics with receipt of trastuzumab in a stage I–III (early) and stage IV (metastatic) HER2+ invasive breast cancer female population using data from a publicly funded healthcare system.